1. Home
  2. SCLX vs ELTX Comparison

SCLX vs ELTX Comparison

Compare SCLX & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$17.70

Market Cap

139.3M

Sector

Health Care

ML Signal

HOLD

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$8.39

Market Cap

158.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCLX
ELTX
Founded
2011
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.3M
158.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SCLX
ELTX
Price
$17.70
$8.39
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
N/A
$13.00
AVG Volume (30 Days)
119.6K
106.1K
Earning Date
11-14-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$40,360,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$749.70
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.60
$4.60
52 Week High
$34.27
$12.62

Technical Indicators

Market Signals
Indicator
SCLX
ELTX
Relative Strength Index (RSI) 44.92 41.65
Support Level $18.34 $7.98
Resistance Level $20.62 $9.00
Average True Range (ATR) 2.14 0.63
MACD -0.28 -0.01
Stochastic Oscillator 1.86 28.06

Price Performance

Historical Comparison
SCLX
ELTX

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.

Share on Social Networks: